Valuation: Cellnovo

Market Cap 2.44M 2.11M 1.98M 1.8M 3.38M 232M 3.44M 23.18M 9.06M 117M 9.14M 8.95M 388M P/E 2018 *
-0.15x
P/E 2019 * -
Enterprise Value 12.46M 10.77M 10.12M 9.2M 17.28M 1.19B 17.59M 119M 46.34M 596M 46.75M 45.76M 1.98B EV / Sales 2018
8.63x
EV / Sales 2019 * -
Free-Float
99.67%
Yield 2018 *
-
Yield 2019 * -
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 2.68M
-3.93%-11.56% - - 12.77B
+2.08%+1.50%-24.34%-43.41% 9.15B
+0.95%-1.70%+1.91%+104.68% 8.1B
+0.34%-17.58%-45.69%+161.27% 4.08B
+1.20%-1.17%-41.24%-17.04% 2.46B
-1.34%-2.65%-34.52%-35.89% 1.92B
+5.92%+6.85%+35.94%+91.43% 1.68B
+2.80%+3.01%+11.01%+68.79% 1.47B
+0.20%+1.01%+0.64%+115.01% 1.38B
Average +0.82%-3.58%-12.04%+55.60% 4.3B
Weighted average by Cap. -0.17%-5.72%-16.00%+46.68%

Financials

2018 2019 *
Net sales 3.32M 2.87M 2.7M 2.45M 4.61M 317M 4.69M 31.61M 12.36M 159M 12.47M 12.2M 529M -
Net income -15.94M -13.78M -12.95M -11.78M -22.11M -1.52B -22.51M -152M -59.29M -762M -59.82M -58.54M -2.54B -
Net Debt 10.02M 8.67M 8.14M 7.41M 13.9M 956M 14.15M 95.37M 37.28M 479M 37.61M 36.81M 1.6B -
Logo Cellnovo
Cellnovo Group SA is a France-based company principally engaged in medical instrument manufacturing . The Company specialized in the development of a mobile system for managing type 1 diabetes. Its apparatus includes a cordless micro-pump (a patch pump), an integrated monitoring device and a cellular handset with touch screen with an embedded blood glucose meter. The Company system enables diabetics to live a normal life whilst closely monitoring their glycaemia, their use of insulin, their activity and their food intake.
Employees
-
  1. Stock Market
  2. Stocks
  3. CLNV Stock